Separating Therapeutically Viable Viral Vectors
Recombinant adeno-associated viruses (rAAVs) containing a corrective gene of interest are excellent nucleic acid delivery vehicles for gene therapies. During rAAV production, only a fraction of AAV capsids package the desired gene of interest properly, the unwanted empty AAV byproducts reduce the therapy’s success. To manufacture pure recombinant viral vectors, researchers implement stringent quality control measures at every step of the production process.
Download this application note from Bio-techne to learn about Simple Western™, an instrument that combines capillary electrophoresis immunodetection to distinguish between empty fully-assembled particles, offering high sensitivity, reproducibility, scalability in rAAV manufacturing.